Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | DRD2 | P14416 | 8/20 | 0.62 |
| ▸ | DRD4 | P21917 | 8/20 | 0.62 |
| ▸ | DRD3 | P35462 | 7/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28255683 | 0.79 | MAPT (0.53) | MAPTNPSR1TDP1L3MBTL1ALDH1A1 | |
| SCHEMBL6888226 | 0.76 | CES1 (0.47) | DRD2DRD4DRD3HTR1AALDH1A1 | |
| SCHEMBL5364887 | 0.76 | DRD2 (0.55) | MAPTNPSR1TDP1L3MBTL1DRD2 | |
| Hydrochloric Acid SCHEMBL11203073 | 0.75 | DRD2 (0.78) | MAPTNPSR1TDP1L3MBTL1DRD2 | |
| SCHEMBL8311608 | 0.74 | MAPT (0.62) | MAPTNPSR1TDP1L3MBTL1DRD2 | |
| SCHEMBL10472333 | 0.71 | DRD4 (0.55) | MAPTNPSR1TDP1L3MBTL1DRD2 | |
| SCHEMBL6864941 | 0.71 | DRD4 (0.81) | DRD2DRD4DRD3ALDH1A1SIGMAR1 | |
| SCHEMBL12000243 | 0.70 | DRD4 (0.64) | MAPTNPSR1TDP1L3MBTL1DRD2 | |
| SCHEMBL1442567 | 0.70 | DRD2 (1.00) | MAPTNPSR1TDP1L3MBTL1DRD2 | |
| SCHEMBL16798770 | 0.70 | CES1 (0.46) | MAPTTDP1DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743796-B2 | PSYCHOLOGICAL DISORDERS; SCHIZOPHRENIA; PARKINSON'S DISEASE | WYETH | 2004-06-01 | — | — | US | claimed |
| US-20030013722-A1 | Psychological disorders; schizophrenia; Parkinson's disease | WYETH | 2003-01-16 | — | — | US | claimed |
| WO-2002090327-A1 | PIPERAZINYL-ISATINS | WYETH (US) | 2002-11-14 | — | — | WO | claimed |
| EP-2032584-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | Wyeth (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20080125469-A1 | Thiadiazole compounds and methods of use thereof | WYETH (US) | 2008-05-29 | — | — | US | disclosed |
| WO-2007146138-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WYETH (US) | 2007-12-21 | — | — | WO | disclosed |
| US-6743796-B2 | PSYCHOLOGICAL DISORDERS; SCHIZOPHRENIA; PARKINSON'S DISEASE | WYETH | 2004-06-01 | — | — | US | disclosed |
| US-20030013722-A1 | Psychological disorders; schizophrenia; Parkinson's disease | WYETH | 2003-01-16 | — | — | US | disclosed |
| WO-2002090327-A1 | PIPERAZINYL-ISATINS | WYETH (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013722-A1 | Psychological disorders; schizophrenia; Parkinson's disease | HTR2C, HTR3C, HTR5A | MAPT 985/4885NPSR1 122/4885TDP1 2020/4885 |
| US-20080125469-A1 | Thiadiazole compounds and methods of use thereof | ADAMTS5, ADAMTS1, TIMP3 | MAPT 1320/4885NPSR1 4269/4885TDP1 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.